TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19601995

Group type: COMPARATOR
Intervention: lopinavir/ritonavir (LPV/r)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: darunavir/ritonavir (DRV/r)
Number of subjects: 0
Study: 15733519

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg/day
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 12796602

Group type: COMPARATOR
Intervention: Cefepime (C)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Ticarcillin and clavulanate potassium and aztreonam (T/A)
Number of subjects: 126
Study: 10596204

Group type: EXPERIMENTAL
Intervention: Cisatracurium priming (0.01 mg/kg)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Pancuronium priming (0.015 mg/kg)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control (sodium chloride priming)
Number of subjects: 45
Study: 8698586

Group type: EXPERIMENTAL
Intervention: Self-reported morbidities and functional health status
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Functional and perceived health status, demographic characteristics, and diagnoses
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Functional/perceived health status scales and disease classes
Number of subjects: 100
Study: 1882007

Group type: EXPERIMENTAL
Intervention: Buspirone, 15 mg per day
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 7050711

Group type: EXPERIMENTAL
Intervention: Zomepirac sodium
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 31655801

Group type: EXPERIMENTAL
Intervention: Ridaforolimus-eluting stents
Number of subjects: 2201

Group type: COMPARATOR
Intervention: Zotarolimus-eluting stents
Number of subjects: 2201
Study: 28981503

Group type: EXPERIMENTAL
Intervention: Topical formulation of leaf of Juniperus excelsa extract plus cryotherapy
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo plus cryotherapy
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Topical formulation of leaf of Juniperus excelsa extract
Number of subjects: 72
Study: 27017763

Group type: EXPERIMENTAL
Intervention: Group F (low-dose and addition of fentanyl): received intrathecally 0.5% hyperbaric bupivacaine (70% of group B) with fentanyl 20 mg and epidural catheter at T12‐L1.
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Group E (low-dose and epidural volume extension): received intrathecally 0.5% hyperbaric bupivacaine (70% of group B) and epidural catheter at L3‐4, with 10 ml saline injected 3 minutes after intrathecal injection.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Group B (conventional dose): received intrathecally 0.5% hyperbaric bupivacaine (10 mg; < 160 cm in height 11 mg; > 160 cm in height) and epidural catheter at T12‐L1.
Number of subjects: 60
Study: 24463478

Group type: COMPARATOR
Intervention: Sufentanil PCA
Number of subjects: 120

Group type: COMPARATOR
Intervention: Dexmedetomidine bolus (0.5μg/kg) after delivery and sufentanil PCA
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine bolus (0.5μg/kg) after delivery and sufentanil with dexmedetomidine PCA (background infusion of 0.045μg/kg/h with a bolus of 0.07μg/kg)
Number of subjects: 120
Study: 21870106

Group type: EXPERIMENTAL
Intervention: Berberine (300 mg, t.i.d., p.o.)
Number of subjects: 0
Study: 19608826

Group type: EXPERIMENTAL
Intervention: IV alanyl-glutamine supplementation (0.5 g x kg(‐1) x d(‐1))
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control solution without alanyl-glutamine
Number of subjects: 40
Study: 18215726

Group type: EXPERIMENTAL
Intervention: Donepezil (5 mg/d for 6 weeks, then increased to 10 mg/d for 20 weeks)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 16383244

Group type: EXPERIMENTAL
Intervention: Endoscopic third ventriculostomy combined with choroid plexus cauterization (ETV-CPC); mean follow-up of 9.2 months.
Number of subjects: 550

Group type: COMPARATOR
Intervention: Endoscopic third ventriculostomy alone (ETV); mean follow-up of 19 months.
Number of subjects: 550

Group type: EXPERIMENTAL
Intervention: ETV-CPC in patients with myelomeningocele;
Number of subjects: 550

Group type: EXPERIMENTAL
Intervention: ETV-CPC in patients with nonpostinfectious hydrocephalus (NPIH);
Number of subjects: 550

Group type: EXPERIMENTAL
Intervention: ETV-CPC in patients with postinfectious hydrocephalus (PIH);
Number of subjects: 550

Group type: COMPARATOR
Intervention: ETV and ETV-CPC for patients at least 1 year of age;
Number of subjects: 550

Group type: EXPERIMENTAL
Intervention: Overall surgical mortality rate;
Number of subjects: 550

Group type: EXPERIMENTAL
Intervention: Overall infection rate;
Number of subjects: 550
Study: 12401535

Group type: EXPERIMENTAL
Intervention: Infliximab plus methotrexate for 54 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Methotrexate alone
Number of subjects: 0
Study: 9803104

Group type: EXPERIMENTAL
Intervention: Abdominal ultrasound and plain film radiography evaluated by senior radiologists
Number of subjects: 95

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 95
Study: 7647726

Group type: EXPERIMENTAL
Intervention: Pollinex
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 2694203

Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 140698

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide
Number of subjects: 16

Group type: COMPARATOR
Intervention: Deptropine citrate
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 31790884

Group type: COMPARATOR
Intervention: Distraction
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Abstract rumination
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Concrete rumination
Number of subjects: 116
Study: 30888593

Group type: EXPERIMENTAL
Intervention: Low-calorie diet (LCD) with Modifast (800 kcal/day) during 2 weeks
Number of subjects: 62

Group type: COMPARATOR
Intervention: Omega-3 fatty acids (2 g/day) with a normal diet (2000 kcal/day) during 4 weeks
Number of subjects: 62
Study: 27984004

Group type: EXPERIMENTAL
Intervention: High positive end-expiratory pressure strategy
Number of subjects: 505

Group type: COMPARATOR
Intervention: Low positive end-expiratory pressure strategy
Number of subjects: 505
Study: 26025322

Group type: EXPERIMENTAL
Intervention: Digoxin therapy
Number of subjects: 1820
Study: 23953895

Group type: EXPERIMENTAL
Intervention: Extracorporeal shockwave therapy (ESWT) - 4000 pulses at 0.25 mJ/mm² weekly for 4 weeks
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo - shockwave at 0 mJ/mm²
Number of subjects: 70
Study: 21765233

Group type: EXPERIMENTAL
Intervention: Postoperative drain clamping for 2 hours without intraoperative bleeding control (Group A)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Intraoperative bleeding control without postoperative drain clamping (Group B)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Both groups (A and B)
Number of subjects: 71
Study: 19369294

Group type: EXPERIMENTAL
Intervention: Mifepristone 25 mg given twice on day 1 followed by 4 days of EE 20 microg
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Mifepristone 25 mg given twice on day 1 plus doxycycline 100 mg twice daily for 5 days
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Doxycycline 100 mg twice daily for 5 days
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Doxycycline 100 mg twice daily with EE 20 microg daily
Number of subjects: 204

Group type: COMPARATOR
Intervention: Placebo twice daily for 5 days
Number of subjects: 204
Study: 17060732

Group type: EXPERIMENTAL
Intervention: High magnification assessment with the Varioscope (7X magnification)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group using frozen section and permanent section analysis
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: High magnification assessment
Number of subjects: 40
Study: 12548256

Group type: EXPERIMENTAL
Intervention: Aloe vera gel gloves used 8 hours/day for 30 days
Number of subjects: 29

Group type: COMPARATOR
Intervention: No use of aloe vera gel gloves (control)
Number of subjects: 29
Study: 11129359

Group type: EXPERIMENTAL
Intervention: Baby contact (holding baby) during laboratory stress assessment
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Oxytocin increase group (mothers with increased plasma OT after baby contact)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Oxytocin decrease group (mothers with decreased plasma OT after baby contact)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Breast-feeding mothers (OT increase group)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Bottle-feeding mothers (OT decrease group)
Number of subjects: 25
Study: 8695134

Group type: EXPERIMENTAL
Intervention: Desflurane anesthesia with mivacurium infusion
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Isoflurane anesthesia with mivacurium infusion
Number of subjects: 41

Group type: COMPARATOR
Intervention: Both groups (Desflurane and Isoflurane)
Number of subjects: 41
Study: 1627030

Group type: EXPERIMENTAL
Intervention: Serum cholesterol level measured at initial screening
Number of subjects: 350977

Group type: EXPERIMENTAL
Intervention: Serum cholesterol level less than 4.14 mmol/L (less than 160 mg/dL)
Number of subjects: 350977

Group type: EXPERIMENTAL
Intervention: Serum cholesterol level
Number of subjects: 350977
Study: 6439955

Group type: EXPERIMENTAL
Intervention: Experimental behavioral program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no behavioral strategies)
Number of subjects: 0
Study: 31476159

Group type: EXPERIMENTAL
Intervention: Higher BMI levels
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Worse metabolic biomarker profiles
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Leptin
Number of subjects: 160
Study: 28318850

Group type: EXPERIMENTAL
Intervention: Hyperosmolar irrigation solution (593 mOsm/L)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Isotonic irrigation solution (273 mOsm/L)
Number of subjects: 50
Study: 26828770

Group type: EXPERIMENTAL
Intervention: Individually delivered cognitive behavioral therapy (n = 62)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Cognitive processing therapy (n = 61)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Group-delivered integrated cognitive behavioral therapy
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Cognitive processing therapy
Number of subjects: 146
Study: 25028274

Group type: EXPERIMENTAL
Intervention: Oral sulfate solution (OSS)
Number of subjects: 338

Group type: COMPARATOR
Intervention: Sodium picosulfate plus magnesium citrate (SP+MC)
Number of subjects: 338
Study: 22389080

Group type: EXPERIMENTAL
Intervention: Cocaine dependent individuals exposed to stress imagery
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Cocaine dependent individuals at baseline
Number of subjects: 28

Group type: COMPARATOR
Intervention: Social drinkers exposed to drug cue imagery
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Cocaine dependent individuals exposed to relaxing imagery
Number of subjects: 28
Study: 18586273

Group type: EXPERIMENTAL
Intervention: risperidone (0.5-3mg/day)
Number of subjects: 97

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: risperidone
Number of subjects: 97
Study: 17596576

Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 17313

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17313
Study: 15669590

Group type: EXPERIMENTAL
Intervention: Lumbotomic access
Number of subjects: 94

Group type: COMPARATOR
Intervention: Laparotomic access
Number of subjects: 94
Study: 12453549

Group type: EXPERIMENTAL
Intervention: General practitioners' management of patients with heart failure based on symptoms and signs alone.
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Chest X-ray and electrocardiogram arrangements for diagnosis.
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Trial of diuretics for diagnosis.
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Obstacles to diagnosis and management of heart failure.
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Awareness of the impact of angiotensin‐converting enzyme inhibitors.
Number of subjects: 18
Study: 11289568

Group type: EXPERIMENTAL
Intervention: 10 mg vardenafil
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 20 mg vardenafil
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 9165135

Group type: EXPERIMENTAL
Intervention: 66 Gy in 33 2 Gy twice daily fractions in 22-25 days (b.i.d.)
Number of subjects: 82

Group type: COMPARATOR
Intervention: 66 Gy in 33 2 Gy daily fractions in 45-48 days (o.d.)
Number of subjects: 82
Study: 11767423

Group type: EXPERIMENTAL
Intervention: Affirmative and non-affirmative suggestions
Number of subjects: 82

Group type: COMPARATOR
Intervention: Affirmative suggestions
Number of subjects: 82

Group type: COMPARATOR
Intervention: Non-affirmative suggestions
Number of subjects: 82

Group type: COMPARATOR
Intervention: Irrelevant text
Number of subjects: 82
Study: 3119481

Group type: EXPERIMENTAL
Intervention: Standard solution containing crystalline amino acids (3.8 g/l), xylitol (25 g/l) and sorbitol (25 g/l), accounting for a total of 900 cal/day
Number of subjects: 31

Group type: COMPARATOR
Intervention: Water, electrolytes and glucose
Number of subjects: 31
Study: 29316945

Group type: EXPERIMENTAL
Intervention: Academic detailing visit on appropriate prescribing of pain relief medication
Number of subjects: 3529

Group type: COMPARATOR
Intervention: Control group (no academic detailing visit)
Number of subjects: 3529
Study: 27517163

Group type: EXPERIMENTAL
Intervention: Same-admission cholecystectomy
Number of subjects: 264

Group type: COMPARATOR
Intervention: Interval cholecystectomy
Number of subjects: 264
Study: 24746411

Group type: EXPERIMENTAL
Intervention: Pulverized brand-name and generic drugs containing amlodipine (Norvasc(®), Amlodipin‐Mepha(®), Amlodipin Pfizer(®))
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Pulverized brand-name and generic drugs containing candesartan (Atacand(®), Cansartan‐Mepha(®), Pemzek(®))
Number of subjects: 31
Study: 23570051

Group type: EXPERIMENTAL
Intervention: 2010-2011 non-adjuvanted TIV (Fluviral®, GSK Canada)
Number of subjects: 326

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 326
Study: 19838801

Group type: EXPERIMENTAL
Intervention: Cyclic meditation (CM)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Supine rest (SR)
Number of subjects: 30
Study: 18785556

Group type: EXPERIMENTAL
Intervention: Composite graft group (enriched bone marrow mesenchymal stem cells hybridized with beta‐tri calcium phosphate)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Autograft group (autologous iliac crest bone graft)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Composite graft group
Number of subjects: 56

Group type: COMPARATOR
Intervention: Autograft group
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 56
Study: 16841035

Group type: EXPERIMENTAL
Intervention: Fractionated PDT (2-fold illumination scheme with two light fractions of 20 and 80 J cm(‐2))
Number of subjects: 154

Group type: COMPARATOR
Intervention: Single illumination (75 J cm(‐2))
Number of subjects: 154
Study: 14706729

Group type: EXPERIMENTAL
Intervention: Alternative monotherapy
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Adjunctive therapy
Number of subjects: 157
Study: 10803803

Group type: EXPERIMENTAL
Intervention: L-acetylcarnitine
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 8641911

Group type: EXPERIMENTAL
Intervention: Adjuvant therapy consisting of prophylactic hepatic irradiation and pancreatic bed irradiation with concurrent infusional 5‐fluorouracil (200 mg/m2/day) and leucovorin (5 mg/m2/day) for 5 out of every 7 days during the 38‐day treatment sequence.
Number of subjects: 14
Study: 1555461

Group type: EXPERIMENTAL
Intervention: 30 percent O2
Number of subjects: 15

Group type: COMPARATOR
Intervention: Room air
Number of subjects: 15
Study: 31986997

Group type: EXPERIMENTAL
Intervention: Higher resilience
Number of subjects: 105
Study: 29801061

Group type: EXPERIMENTAL
Intervention: MC1R test offer
Number of subjects: 499

Group type: COMPARATOR
Intervention: Usual-care condition (National Cancer Institute skin cancer pamphlet)
Number of subjects: 499
Study: 27590876

Group type: EXPERIMENTAL
Intervention: Fructose feeding
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Glucose feeding
Number of subjects: 20
Study: 25245353

Group type: EXPERIMENTAL
Intervention: GXR AM + psychostimulant
Number of subjects: 461

Group type: EXPERIMENTAL
Intervention: GXR PM + psychostimulant
Number of subjects: 461

Group type: COMPARATOR
Intervention: Placebo + psychostimulant
Number of subjects: 461
Study: 22646297

Group type: EXPERIMENTAL
Intervention: Direct correlation small group sessions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control method (identical laboratory and teaching conditions without simultaneous correlation)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cross-over group preference
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Correlation teaching sessions
Number of subjects: 0
Study: 19892408

Group type: EXPERIMENTAL
Intervention: Propofol 0.5mg/kg 15s post-stimulus
Number of subjects: 15

Group type: COMPARATOR
Intervention: No propofol
Number of subjects: 15
Study: 18277843

Group type: EXPERIMENTAL
Intervention: Transillumination using Veinlite
Number of subjects: 240

Group type: COMPARATOR
Intervention: Nontransillumination (control group)
Number of subjects: 240
Study: 16489968

Group type: EXPERIMENTAL
Intervention: Biphasic insulin aspart (BIAsp)
Number of subjects: 167

Group type: COMPARATOR
Intervention: Human insulin
Number of subjects: 167
Study: 14609904

Group type: EXPERIMENTAL
Intervention: Children with symptoms consistent with nonspecific functional abdominal pain
Number of subjects: 0

Group type: COMPARATOR
Intervention: Children with symptoms of irritable bowel syndrome or functional dyspepsia
Number of subjects: 0
Study: 10841227

Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitor (ACEi)
Number of subjects: 96712

Group type: COMPARATOR
Intervention: Control
Number of subjects: 96712
Study: 9443518

Group type: EXPERIMENTAL
Intervention: 15 mg diazepam
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 30 mg oxazepam
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 7.5 mg zopiclone
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 15 mg zolpidem
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 0.65+0.35 g/kg ethanol
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 8450161

Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy
Number of subjects: 148
Study: 3777111

Group type: EXPERIMENTAL
Intervention: Group A (12 sessions of 10-min each)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Group B (6 sessions of 20-min each)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Group C (3 sessions of 40-min each)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Group D (control group)
Number of subjects: 20
Study: 30572906

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26967896

Group type: EXPERIMENTAL
Intervention: Succinylcholine (0.8 mg/kg)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Rocuronium (0.4 mg/kg)
Number of subjects: 45
Study: 25012985

Group type: EXPERIMENTAL
Intervention: Telotristat etiprate 150, 250, 350, or 500 mg tid
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Telotristat etiprate 500 mg tid
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Telotristat etiprate
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 22660484

Group type: EXPERIMENTAL
Intervention: Perivascular ultrasound-guided axillary brachial plexus block
Number of subjects: 50

Group type: COMPARATOR
Intervention: Perineural ultrasound-guided axillary brachial plexus block
Number of subjects: 50
Study: 20441134

Group type: EXPERIMENTAL
Intervention: Experiencing role as player
Number of subjects: 0

Group type: COMPARATOR
Intervention: Experiencing role as spectator
Number of subjects: 0
Study: 18546285

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTX‐A) 20-190 units
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTX‐A)
Number of subjects: 29
Study: 15753790

Group type: EXPERIMENTAL
Intervention: 18F-FDG-PET imaging at 2 hours
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 18F-FDG-PET imaging at 3 hours
Number of subjects: 12

Group type: COMPARATOR
Intervention: 18F-FDG-PET imaging at 1 hour
Number of subjects: 12
Study: 12434942

Group type: EXPERIMENTAL
Intervention: SCT+MI
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: SCT-only
Number of subjects: 53

Group type: COMPARATOR
Intervention: Education-only
Number of subjects: 53
Study: 10367620

Group type: EXPERIMENTAL
Intervention: PTSD-positive veterans
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Anxiety disorders
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Depressed veterans
Number of subjects: 286
Study: 7724298

Group type: EXPERIMENTAL
Intervention: Glucose-based oral rehydration solution (Pedialyte)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Rice syrup solids-based ORS (Infalyte)
Number of subjects: 60
Study: 2029011

Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Captopril 25 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (Group A)
Number of subjects: 20
Study: 7273791

Group type: EXPERIMENTAL
Intervention: Five-drug combination chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single agent sequential treatment
Number of subjects: 0
Study: 28965435

Group type: EXPERIMENTAL
Intervention: Neopuff (early continuous positive airway pressure via T-piece-based infant resuscitator) for 20 minutes
Number of subjects: 64

Group type: COMPARATOR
Intervention: Free flow O2 (control group)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Neopuff
Number of subjects: 64
Study: 28207264

Group type: EXPERIMENTAL
Intervention: Automated approach to detect and cure incorrect orbital convergence
Number of subjects: 0
Study: 24792011

Group type: EXPERIMENTAL
Intervention: Preperitoneal mesh repair
Number of subjects: 60

Group type: COMPARATOR
Intervention: Preaponeurotic mesh repair
Number of subjects: 60
Study: 24260764

Group type: EXPERIMENTAL
Intervention: Erdosteine only
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combination of erdosteine and nasal corticosteroid spray
Number of subjects: 0